New Cystic Fibrosis Treatment

Cystic fibrosis is a genetic diseases that prohibits people from being able to breath over time.  At the moment, there is no cure for the disease (although there are many treatments) but a new potential form of treatment has been found to work significantly better than the others.


The research was done by an international team of researchers from the George Washington (GW) University in Washington, D.C., in collaboration with the University of Perugia and the University of Rome (both in Italy) who discovered a drug that could potentially treat the progression of cystic fibrosis – THYMOSIN ALPHA 1 (Ta1) – also known as ‘Zadaxin’ which is already used in treating many viral infections and disorders such as HIV.

This drug has been known to have a role in immunity and reduces inflammation as well as being able to correct genetic defects. As a result, during the study the researchers found that the Ta1 corrected the defects in the tissue of mice and improved the activity of Cystic Fibrosis transmembrane conductance regulator (CFTR) that is associated with balancing he levels of salt and water in the lungs.

Allan L. Goldstein, Ph.D., study co-author and Professor Emeritus in Residence of biochemistry and molecular medicine at the GW School of Medicine and Health Sciences said this:

“Right now there are multiple treatments for cystic fibrosis, and while these have improved life expectancy dramatically, there is still only a lifespan of about 40 years for patients. No one treatment can stand alone. We developed a single treatment that can potentially correct the genetic defect that causes cystic fibrosis and decrease the inflammation that happens as a result.”

Hopefully, this finding will enable Cystic Fibrosis to be tackled more efficiently, and maybe even work towards a potential cure.


Thank you for reading this blog, if you enjoyed reading about the potential new treatment for Cystic Fibrosis please leave a rating and comment down below what you would like to read next!



Sources used:


Leave a Reply

Your email address will not be published. Required fields are marked *